Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. - Wikidata - awgldk - TriplyDB

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

http://www.wikidata.org/entity/Q53185818

about

Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature The myth of schizophrenia as a progressive brain disease Quetiapine versus other atypical antipsychotics for schizophrenia Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery.Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia Identification of targeted analyte clusters for studies of schizophrenia.Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond.The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.Effect of second-generation antipsychotics on cognition: current issues and future challenges.Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study.Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients Early developmental disturbances of cortical inhibitory neurons: contribution to cognitive deficits in schizophrenia.Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders Use of eye movement monitoring to examine item and relational memory in schizophrenia.Cognition in schizophrenia: Past, present, and future.Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.Antipsychotic medications and cognitive functioning in bipolar disorder: moderating effects of COMT Val108/158 Met genotype.Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response-a prospective open-label study.Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.Neural correlates of relational and item-specific encoding during working and long-term memory in schizophrenia.Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically?: Results from the Changsha study Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders"Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing.EARLY DETECTION AND INTERVENTION FOR PSYCHOSIS: PERSPECTIVES FROM NORTH AMERICA.Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia Olanzapine Prevents the PCP-induced Reduction in the Neurite Outgrowth of Prefrontal Cortical Neurons via NRG1 Aerobic exercise and yoga improve neurocognitive function in women with early psychosis The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China.Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study.

P2860

Q22241267-62A8524B-02B7-4AA5-9391-ACF1256981EA Q24067152-6871E2D7-1AAB-4A45-8174-A0F55C65D262 Q24202427-57BCE1B0-B561-43FE-844B-95DAB43ED46F Q26770497-C3E773CC-DAF9-45E8-942C-1E715869814C Q30406145-7A8F6447-977E-4398-A772-885DEEB49A9C Q30454958-DF9C85A0-1DF0-469C-9238-188C51519C12 Q30459624-707F4451-2D8E-4D47-856B-63112743D68D Q30476776-E44CF901-3577-4487-9957-A70F7A78E16F Q33566114-2CE7B100-A4E7-41B3-9180-8DD5C7A339DE Q33605308-20FE9702-8623-4622-90D4-DBE5C577B06D Q33680103-C03B0D20-BBF5-4254-9188-F85E03B2C533 Q33888153-F411434F-C9A6-4B5B-8EC4-91FC4AD72E10 Q33933877-131A60FB-1904-4684-A774-4C80DD0275E6 Q33936458-68856EA7-5DD9-4EE4-B700-1134E1993243 Q34048663-61B45E22-9A0C-4C36-94D3-BF597468A734 Q34082617-0FFFCE53-2DEB-4872-ADEC-F976B30C259C Q34095720-0D5C49F8-E920-4F6B-A78D-B9F315F723C8 Q34143036-2E82F256-E17A-417C-8290-553085D2B823 Q34224025-350FABBD-00ED-48D8-9B92-21D3E773A148 Q34249753-4812DF89-1E10-4FD0-99C4-74F90B9BD321 Q34591845-6934FC54-C76F-4037-ACD4-9139DA23FE26 Q34661875-BB28B0D8-7AE4-4BCC-8109-7843135A8B23 Q34665354-800696F2-A3D3-4F2A-8529-FE9BAC85F4EE Q35021026-DBD557A8-5A8A-4884-B262-C3222A22C7BC Q35110274-370F3C1F-BB47-4870-8F84-85BFAB92CD20 Q35592752-659ED606-41D4-4D7D-AF43-490EA5A10780 Q35748684-C23BE29A-5D22-41CD-AA21-F8D2508F2FDE Q35873996-36F6E7A5-6FAD-4F87-A72B-8CC880C3488C Q35941992-DABAC9F5-BD11-49F0-9481-C0958B0C234D Q35946867-CD7F8C89-0294-47DA-929C-FE57030541A3 Q36033253-C201086B-E2A4-429C-A389-09040E910F0A Q36148536-12D3910C-219C-4E3F-8087-7492F413F323 Q36221808-4E65DEEF-2180-4038-885E-BB7BF75C7130 Q36318838-C47FCD9F-FB9A-4C1A-A532-21A3C9340889 Q36377916-82194B9E-139B-486A-9B11-DD0651161D55 Q36500134-7A4A12F4-6F55-46E3-B078-A143EDA53CC6 Q36848342-89267531-712C-4E7C-A8B4-32A1F6969DF8 Q37028673-A527AA73-0A70-4DF1-A898-565D6A75D1DB Q37076464-B9CED1C4-A18F-471F-B88A-3FA35AD2B07E Q37221567-12F635CB-149E-4AA0-BF44-35B601E0C25F

P2860

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

http://www.wikidata.org/entity/Q53185818

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Effects of olanzapine, quetiap ...... uble-blind 52-week comparison.

@en

Effects of olanzapine, quetiap ...... uble-blind 52-week comparison.

@nl

type

label

Effects of olanzapine, quetiap ...... uble-blind 52-week comparison.

@en

Effects of olanzapine, quetiap ...... uble-blind 52-week comparison.

@nl

prefLabel

Effects of olanzapine, quetiap ...... uble-blind 52-week comparison.

@en

Effects of olanzapine, quetiap ...... uble-blind 52-week comparison.

@nl

P1433

Q53185818-5287FAF2-E7F4-41AC-8C81-B35674A7253E

P1476

Q53185818-818E97BF-E8E9-46CA-8E64-F4F35E122D34

P2093

Q53185818-05F6C6F6-84B0-4E20-8DC6-78D442216B0C

Q53185818-07862E5D-F4B0-490F-B1BE-F181E29E089E

Q53185818-165AF7A0-8EBD-4093-AD1C-1FDCDAE789CE

Q53185818-861C6425-1FF3-4EE1-AE6E-61953B9070A0

Q53185818-D9270436-2ECC-459E-A557-369BA8885846

Q53185818-E8E96BCE-4AF7-421D-A148-B0D4B66DA9E5

P304

Q53185818-A6175CC8-3D8F-4FC0-A855-F751BFB6B577

P31

Q53185818-3090E62F-2535-4D9F-989D-B06CD47581D1

P356

Q53185818-E7AF89EC-E223-4144-961C-2CF12D41F76A

P407

Q53185818-C339BEE9-B7A8-44A0-97F0-2BDC2F8A57DA

P433

Q53185818-43C66891-3D88-4B61-AC2C-B615BA752EB8

P478

Q53185818-E9B1F3B8-C2CF-4FB5-8B2F-A84E0114989A

P50

Q53185818-713EBFF3-617A-40A7-A367-46A7AA075E61

P577

Q53185818-E05967B4-73FD-47B1-8966-20B709D3E152

P698

Q53185818-7AE667B0-7071-495B-8590-AD01FAFCF93B

P921

Q53185818-103EF547-B72F-47DC-895F-6F407A386811

P356

AJP.2007.164.7.1061

P1433

American Journal of Psychiatry

P1476

Effects of olanzapine, quetiap ...... uble-blind 52-week comparison.

@en

P2093

Diana O Perkins

http://www.w3.org/2001/XMLSchema#string

Hongbin Gu

http://www.w3.org/2001/XMLSchema#string

John A Sweeney

http://www.w3.org/2001/XMLSchema#string

Joseph P McEvoy

http://www.w3.org/2001/XMLSchema#string

Richard S E Keefe

http://www.w3.org/2001/XMLSchema#string

Robert M Hamer

http://www.w3.org/2001/XMLSchema#string

P304

1061-1071

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1176/AJP.2007.164.7.1061

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

164

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey Lieberman

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17606658

http://www.w3.org/2001/XMLSchema#string

P921